Terms: = Germ cell tumor AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
57 results:
1. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical correlates of her3 expression highlights its potential role as a therapeutic target in melanoma.
Shteinman ER; Vergara IA; Rawson RV; Lo SN; Maeda N; Koyama K; da Silva IP; Long GV; Scolyer RA; Wilmott JS; Menzies AM
Pathology; 2023 Aug; 55(5):629-636. PubMed ID: 37286471
[TBL] [Abstract] [Full Text] [Related]
3. Collectin-11 promotes cancer cell proliferation and tumor growth.
Wang JX; Cao B; Ma N; Wu KY; Chen WB; Wu W; Dong X; Liu CF; Gao YF; Diao TY; Min XY; Yong Q; Li ZF; Zhou W; Li K
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36883567
[TBL] [Abstract] [Full Text] [Related]
4. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract] [Full Text] [Related]
5. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
6. Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.
Wang J; Li Z; Yin F; Zhang R; Zhang Y; Wang Z; Sheng X
Cancer Gene Ther; 2022 Mar; 29(3-4):253-263. PubMed ID: 33742130
[TBL] [Abstract] [Full Text] [Related]
7. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
Tiago M; Capparelli C; Erkes DA; Purwin TJ; Heilman SA; Berger AC; Davies MA; Aplin AE
Br J Cancer; 2020 Mar; 122(6):789-800. PubMed ID: 31932756
[TBL] [Abstract] [Full Text] [Related]
8. Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
Liang WS; Dardis C; Helland A; Sekar S; Adkins J; Cuyugan L; Enriquez D; Byron S; Little AS
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30322893
[TBL] [Abstract] [Full Text] [Related]
9. germline single nucleotide polymorphisms in erbb3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D; Eustace A; Toomey S; Cremona M; Milewska M; Furney S; Carr A; Fay J; Kay E; Kennedy S; Crown J; Hennessy B; Madden S
PLoS One; 2018; 13(8):e0200996. PubMed ID: 30071039
[TBL] [Abstract] [Full Text] [Related]
10. Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study.
Izycka-Swieszewska E; Bien E; Stefanowicz J; Szurowska E; Szutowicz-Zielinska E; Koczkowska M; Sigorski D; Kloc W; Rogowski W; Adamkiewicz-Drozynska E
Biomed Res Int; 2018; 2018():4596812. PubMed ID: 29805974
[TBL] [Abstract] [Full Text] [Related]
11. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
[No Abstract] [Full Text] [Related]
12. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
[TBL] [Abstract] [Full Text] [Related]
13. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.
Amsbaugh MJ; Yusuf MB; Gaskins J; Burton EC; Woo SY
Cancer; 2017 Sep; 123(17):3277-3284. PubMed ID: 28452053
[TBL] [Abstract] [Full Text] [Related]
14. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract] [Full Text] [Related]
15. MITF depletion elevates expression levels of erbb3 receptor and its cognate ligand NRG1-beta in melanoma.
Alver TN; Lavelle TJ; Longva AS; Øy GF; Hovig E; Bøe SL
Oncotarget; 2016 Aug; 7(34):55128-55140. PubMed ID: 27391157
[TBL] [Abstract] [Full Text] [Related]
16. Adjuvant Radiation Therapy and Chemotherapy in Merkel cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.
Bhatia S; Storer BE; Iyer JG; Moshiri A; Parvathaneni U; Byrd D; Sober AJ; Sondak VK; Gershenwald JE; Nghiem P
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27245173
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of Nucleotide Synthesis Targets Brain tumor Stem cells in a Subset of Glioblastoma.
Laks DR; Ta L; Crisman TJ; Gao F; Coppola G; Radu CG; Nathanson DA; Kornblum HI
Mol Cancer Ther; 2016 Jun; 15(6):1271-8. PubMed ID: 27196770
[TBL] [Abstract] [Full Text] [Related]
18. Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma tumor Growth through Inhibition of Notch1 and erbb3.
Zhang K; Wong P; Salvaggio C; Salhi A; Osman I; Bedogni B
J Invest Dermatol; 2016 Feb; 136(2):464-472. PubMed ID: 26967479
[TBL] [Abstract] [Full Text] [Related]
19. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract] [Full Text] [Related]
20. Combination of antibodies directed against different erbb3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract] [Full Text] [Related]
[Next]
